



For Immunization Managers

RSV Vaxview

WEEKLY | RSV VACCINATION DASHBOARD



Weekly Respiratory Syncytial Virus (RSV) Vaccination Dashboard

The Weekly RSV Vaccination Dashboard is designed to share weekly RSV vaccination data, including coverage estimates and intent for vaccination, using a variety of data sources including surveys, healthcare claims, electronic medical records, and immunization information systems (IIS) data. The Dashboard will be updated weekly as new data become available. Please [email](#) to share any feedback.

Data Summary

Adults 60+ Coverage (NIS)

[Data and Charts for Adults 60+ Coverage >](#)

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among [adults 60 years and older](#) are based on data from CDC's National Immunization Survey-Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report.

- As of March 31, 2024, an estimated 23.6% (95% Confidence Interval: 22.8%-24.5%) of adults 60 years and older reported having received an RSV vaccine.

- An additional 8.5% (6.1%-10.8%) reported that they definitely plan to get vaccinated.
 - White adults had higher vaccination coverage than adults in all other race and ethnicity groups, with coverage ranging from 10.7% (6.7%-14.6%) among Pacific Islander and Native Hawaiian adults to 25.7% (24.7%-26.8%) among non-Hispanic White adults.
 - Vaccination coverage has also consistently varied by age, poverty status, health insurance status, urbanicity, sex, race and ethnicity, sexual orientation, gender identity, and chronic medical condition.
 - Across states and the District of Columbia, receipt of an RSV vaccine was lowest in Mississippi [15.3% (11.3%-19.3%)] and highest in Michigan [34.9% (27.9%-41.8%)].
 - Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are [available](#).
-

Vaccine Administration and Coverage by Jurisdiction (IIS)

[Data and Charts for Vaccine Administration and Coverage by Jurisdiction >](#)

Monthly Jurisdiction Vaccine Administration and Coverage (IIS)

RSV vaccination coverage estimates as of the end of February 2024 based on IIS data submitted to CDC by 52 immunization awardee jurisdictions.

- Among the currently reporting 44 state and city IIS jurisdictions, RSV vaccination coverage among adults 60 years and older ranged from 0.9% to 20.4%. Among 8 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.0% to 4.1%.
-

Adults 65+ Coverage (CMS)

[Data and Charts for Adults 65+ Coverage >](#)

Adults 65 Years and Older (Medicare Fee-for-service) RSV Vaccination Coverage

RSV vaccination coverage among [Medicare fee-for-service beneficiaries 65 years and older](#)  and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services.

- As of January 27, 2024, an estimated 18.7% of Medicare fee-for-service beneficiaries 65 years and older enrolled in Part D plan were vaccinated.
 - Estimates by race and ethnicity group: 5.1% of Hispanic adults, 9.9% of Black, non-Hispanic adults, 19.5% of White, non-Hispanic adults, 18.3% of adults of Other, non-Hispanic race and ethnicity, and 14.3% of Asian, non-Hispanic adults were vaccinated.
-

Adult Vaccinations Administered (IQVIA)

[Data and Charts for Adult Vaccinations Administered >](#)

RSV Vaccinations Administered in Pharmacies and Medical Offices (Data Source: IQVIA)

RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for [adults 60 years and older](#) based on healthcare claims data.

- As of March 16, 2024, an estimated 9.89 million doses were administered in retail pharmacies and an estimated 326,092 doses were administered in physicians' medical offices to adults 60 years and older.

Pregnant Persons Coverage (VSD)

[Data and Charts for Pregnant Persons Coverage >](#)

Pregnant Persons RSV Vaccination Coverage

RSV vaccination coverage estimates for [pregnant persons](#) 18 to 49 years are based on data from CDC's [Vaccine Safety Datalink](#). Estimates of vaccination coverage are based on electronic health data from multiple integrated health systems.

The period of recommendation for maternal RSV vaccination ended for most of the continental U.S. on January 31, 2024, and data for pregnant persons will not be added beyond January 31, 2024. Estimates for prior weeks will continue to be updated with data for pregnant persons who reached at least 32 weeks gestation and vaccinations received before January 31st, 2024, that were identified retrospectively.

- As of January 31, 2024, among persons who were pregnant and ≥ 32 weeks gestation since September 22, 2023, overall coverage with the RSV vaccine was 17.8%.
- Vaccination coverage was highest among non-Hispanic Asian (24.8%) pregnant persons and lowest among non-Hispanic Black (10.3%) pregnant persons.

Nirsevimab Coverage and Intent for Infants (NIS)

[Data and Charts for Nirsevimab Coverage and Intent for Infants >](#)

Monthly Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females aged 18-49 years with infants under the age of < 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant, are based on data from CDC's National Immunization Survey-Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report.

- As of February 2024, among females with an infant <8 months, 43.0% reported that their infant received nirsevimab.
- An additional 16.7% reported that they definitely plan to get nirsevimab for their infant.
- Among females who were pregnant in February, 38.8% reported that they definitely plan to get nirsevimab for their infant, and among females who are trying to get pregnant, 43.7% reported that they definitely plan to get nirsevimab for their infant.

Nirsevimab Administration and Coverage by Jurisdiction (IIS)

[Data and Charts for Jurisdiction Nirsevimab Administration and Coverage >](#)

Monthly Jurisdiction Nirsevimab Administration and Coverage (IIS)

Nirsevimab administration and coverage estimates among infants aged <8 months as of the end of February 2024 based on IIS data submitted to CDC by 52 immunization awardee jurisdictions. These data do not include doses administered to infants born on or after October 1, 2023, and information on maternal vaccination status is not reported and not considered when calculating nirsevimab coverage.

- Among the currently reporting 44 state and city IIS jurisdictions, nirsevimab coverage among infants <8 months ranged from 2.0% to 22.2%. Among 8 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.0% to 13.5%.

Data & Charts



Adults 60+ Coverage and Intent

(Data Source: NIS)



Vaccine Administration and Coverage by Jurisdiction

(Data Source: IIS)



Adults 65+ Coverage

(Data Source: CMS)



Adult Vaccinations Administered

(Data Source: IQVIA)



Pregnant Persons Coverage

(Data Source: VSD)



Nirsevimab Coverage and Intent for Infants

(Data Source: NIS)



Nirsevimab Administration and Coverage by Jurisdiction

(Data Source: IIS)

Related Pages

Prevent RSV

[Adults 60 years and older](#) and [pregnant persons](#) can protect themselves from RSV.

Learn more about [RSV](#).



Monitoring coverage for recommended vaccinations across the country helps CDC assess how well local areas, states, and the nation are protected from vaccine-preventable diseases. Find vaccination coverage data at:

[ChildVaxView](#)

[SchoolVaxView](#)

[TeenVaxView](#)

[AdultVaxView](#)

[COVIDVaxView](#)

[FluVaxView](#)

[RespVaxView](#)

[GISVaxView](#)